Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Steven Rubin purchased 10,000 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were purchased at an average cost of $1.20 per share, for a total transaction of $12,000.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $12,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Entera Bio Stock Performance

Entera Bio stock traded up $0.14 during mid-day trading on Wednesday, reaching $1.59. 208,487 shares of the company were exchanged, compared to its average volume of 274,594. The firm has a market cap of $72.92 million, a P/E ratio of -6.36 and a beta of 1.84. The business has a fifty day moving average of $1.71 and a 200 day moving average of $2.03. Entera Bio Ltd. has a 12-month low of $1.00 and a 12-month high of $3.22.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Sell-side analysts predict that Entera Bio Ltd. will post -0.28 EPS for the current year.

Institutional Trading of Entera Bio

Several large investors have recently bought and sold shares of ENTX. Citadel Advisors LLC increased its stake in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the period. Finally, Bessemer Group Inc. purchased a new stake in shares of Entera Bio during the second quarter valued at $268,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on ENTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday. Finally, Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, December 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Entera Bio presently has a consensus rating of “Hold” and an average price target of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.